3 US Stocks That May Be Trading Below Estimated Value
In This Article:
As the U.S. market navigates a period of uncertainty with stock futures fluctuating amid anticipation of the presidential election and Federal Reserve's interest rate decision, investors are keenly observing potential opportunities amidst these developments. In this climate, identifying stocks that may be trading below their estimated value can offer a strategic advantage, as undervalued stocks have the potential to provide growth when market conditions stabilize or improve.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Provident Financial Services (NYSE:PFS) | $18.85 | $37.48 | 49.7% |
| Cadence Bank (NYSE:CADE) | $33.06 | $64.76 | 48.9% |
| Atlanticus Holdings (NasdaqGS:ATLC) | $37.28 | $72.49 | 48.6% |
| MVB Financial (NasdaqCM:MVBF) | $19.10 | $37.09 | 48.5% |
| UFP Technologies (NasdaqCM:UFPT) | $272.655 | $539.63 | 49.5% |
| First Western Financial (NasdaqGS:MYFW) | $18.94 | $37.35 | 49.3% |
| Alnylam Pharmaceuticals (NasdaqGS:ALNY) | $273.91 | $546.14 | 49.8% |
| WEX (NYSE:WEX) | $173.79 | $344.90 | 49.6% |
| Alaska Air Group (NYSE:ALK) | $49.23 | $97.63 | 49.6% |
| AeroVironment (NasdaqGS:AVAV) | $216.00 | $419.41 | 48.5% |
We're going to check out a few of the best picks from our screener tool.
ADMA Biologics
Overview: ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of $4.51 billion.
Operations: ADMA's revenue is primarily derived from its Biomanufacturing segment, which accounts for $326.70 million, supplemented by $3.41 million from Plasma Collection Centers.
Estimated Discount To Fair Value: 31.5%
ADMA Biologics is trading at US$19.37, significantly below its estimated fair value of US$28.28, suggesting undervaluation based on cash flows. The company has shown substantial revenue growth, reporting US$107.19 million in Q2 2024 sales compared to US$60.12 million the previous year, and turned profitable with a net income of US$32.06 million versus a prior loss. However, recent insider selling and past shareholder dilution could be potential concerns for investors.
Clorox
Overview: The Clorox Company manufactures and markets consumer and professional products globally, with a market cap of approximately $20.19 billion.